
Antiva Biosciences Reports Phase 1b/2 Data for ABI-2280 in High-Risk Cervical HPV at SGO 2026
Antiva Biosciences Presents Data from Phase 1b/2 Study of ABI-2280 for Treatment of Cervical High-Risk HPV Infection at SGO 2026 Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for…












